Biomarker discovery could lead to urine test for early stage pancreatic cancer
the ONA take:
A three-protein signature that can both identify the most common form of pancreatic cancer at an early stage and distinguish it from chronic pancreatitis has been found by a team of researchers at Barts Cancer Institute, Queen Mary University of London. The discovery could lead to a novel test for screening people at high risk using a urine sample.
Urine samples from patients with pancreatic cancer were found to have higher levels of LYVE1, REG1A, and TFF1, compared with samples from healthy patients; patients with chronic pancreatitis has significantly lower levels of the proteins than those with cancer.
The three proteins were selected for closer examination based on biological information and performance in statistical analysis.
Combined, they form a robust panel that can detect stages I-II pancreatic cancer with over 90% accuracy. Furthermore, using urine, an inert and less complex fluid than blood, is advantageous in that obtaining samples is noninvasive and can be done repeatedly.
The biomarker panel has good specificity and sensitivity. Pancreatic cancer is diagnosed in more than 80% of patients with the disease after it has already spread, significantly reducing eligibility for curative treatment options.
The researchers are hopeful that a simple, inexpensive test can be developed for use in the clinic within the next few years.
A three-protein signature can identify the most common form of pancreatic cancer at an early stage.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Exercise Improves Coping While Undergoing Chemotherapy for Advanced GI Cancer
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
- Evidenced-Based Radiation Treatment Tied to Cost Savings in Early Stage Breast Cancer
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|